March 14, 2024 • 14 mins
Peter talks to Dr Luis Alarcon-Martinez, from the Centre for Eye Research, sharing the latest news on glaucoma research. You can find out more here: https://www.cera.org.au/
See omnystudio.com/listener for privacy information.
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
S1 (00:15):
On Vision Australia Radio this is Vision Xtra with Peter Greco.
S2 (00:22):
Well. Glaucoma week. Glaucoma world glaucoma day. They're very important topics.
Let's chat about it with Doctor Luis Alarcon Martinez from
the center for Eye Research, who is great to catch
up with you. Thanks so much for your time.
S3 (00:35):
It's a pleasure for me being here. Peter, thank you
so much.
S2 (00:37):
We've spoken about glaucoma for many, many years on this program.
You're very much involved with the research. What sort of
areas in the new ways that are being looked at
as far as glaucoma research go?
S3 (00:48):
Well, I mean, we are doing here in in Syria,
we have been doing a lot of things. A lot
of groups are working in trying to, you know, to
solve this disease, to give a better treatment for this disease. And,
and yeah, there are many, many new units. I mean,
we can talk about a couple of them, but particularly
particular what we are doing here in our unit, as
you know, is the neurovascular unit. We are trying to
(01:11):
give a different perspective for the new treatments for glaucoma.
S2 (01:15):
Yeah. Tell us a bit about that because you work
in that neurovascular area. Why is that kind of important.
S3 (01:22):
Yeah, that's a great question Peter. Well, as you know,
glaucoma is is is a neurodegenerative disease, is a disease
that affects the vision of people suffering from this disease.
And we always say that is related to high intraocular pressure,
the pressure that is, you know, into the eye that
is damaging the nerve cells that let us see. So unfortunately,
(01:46):
the treatments that we are having, they are not perfect.
So they can slow the disease, but we cannot cure
the disease. So in our unit, we are trying to
understand how these nerve cells, how these neurons that we
call they talk to the blood vessels, why these blood
vessels are important is because the neurons, the nerve cells
(02:06):
cannot keep energy. So they need to be asking all
the time for these energy to the blood vessels. So
we are thinking that this communication between neurons, nerve cells
and blood vessels is crucial. This is very important in
the in this disease. So we are studying that.
S2 (02:26):
So it's obviously very very what's the word sort of
um down a very micro level if you like. Yeah.
S3 (02:32):
Exactly what we are doing. That's a great point. What
we are doing in our unit is to look at
single nerve cells, one neuron talking to one vessel. So
for that we need a special, you know, equipment that
we are having here now in Sierra.
S2 (02:47):
That's the kind of say the, the the detail and
the communication line.
S3 (02:52):
If it is absolutely, absolutely is to see every single
detail in every single cell after, of course, we are
going to to to see what is happening globally in
the retina. But the first thing is going one by one.
S2 (03:03):
Yeah. And is that, um, you know, different to someone
that could have line of communication if you like. Is
that different to someone with glaucoma? That someone, uh, to
someone who has not got glaucoma?
S3 (03:13):
That's what we are seeing now. Exactly. What we are
seeing is that, uh, that's again, these are great question.
First thing we are trying to say is the, let's
say the the normal communication, let's say the communication in
people without glaucoma, let's say, and then after we are
moving to, to different models we have for glaucoma and
see how this communication is disrupted. But I can say
(03:36):
now here that we are seeing big differences in this
communication in, in, in models of glaucoma in different models
that we are having.
S2 (03:44):
And I guess the next question then is Luis okay, uh,
person I, if you like it is okay doesn't have glaucoma.
Person B does. The communication is different vastly different. What
makes it different. Why does that happen.
S3 (03:57):
Yeah. What we are seeing is that again these neurons
need energy. So we are seeing that these neurons, these
nerve cells again, these cells that let us seen because
it is they take the light and they transform this
light to electrical signal that goes to the brain. So
these neurons that in in people with glaucoma, they are
(04:17):
receiving less energy. So it means that, you know, a
long process in a long term they are going to
these neurons has to be, let's say more tired because yeah,
less energy in a period of a lifetime is going
to be a difference. Of course. Wow.
S2 (04:34):
That's amazing. And I guess, you know, in a sense
we can now understand why. Yeah, the message is, you know,
get yourself tested, uh, often and regularly if, if you
are a person with it in your family because the
earlier you, uh, diagnosis, the earlier you discovered, the more
time people have got for it to be treated and
sort of lessen the harm.
S3 (04:55):
Yes. That's correct. I mean, the idea is that if
this is really we can confirm all these findings, the
idea is to help to these neurons in people with
glaucoma to help. Them to have the energy that they
need all the time by increasing, for example, the blood supply.
By increasing this blood supply or maybe by other, other ways,
(05:15):
maybe keep this energy in a different way. But again,
this is this is the future. I mean, we are
still seeing this is correct. Yeah. Yeah.
S2 (05:23):
That's amazing isn't it? Can that kind of, um, you know,
relationship that communication line is what I'm calling it. Uh, uh,
can that be kind of, uh, replicated or taken to
other parts of the body in terms of, you know,
what happens and what might go wrong? Can you kind of, um,
expand the the research into other areas of the body?
S3 (05:43):
Do you mean, you know, the parts of the body,
like in the brain or something like that?
S2 (05:45):
Yeah, the brain or the heart sort of thing.
S3 (05:48):
Absolutely, absolutely. Uh. That's great. Um, exactly. I mean, what
we are seeing, where we hear we are talking about glaucoma,
but also we are, of course, studying the brain and diseases, uh,
stroke that is very important to all these bands of energy.
And you know, vascular supply etc. is extremely important. And
actually our unit has other, other studies going on in
(06:12):
different diseases related to the brain, for example. Yeah.
S2 (06:14):
The work that you're doing, is it being replicated in
other parts of the world. You kind of, uh, interact
with other, uh, you know, uh, research labs, etc. to
kind of, uh, collaborate and, and, uh, sort of, uh,
make the work, you know, work more, uh, you know,
more targeted, if I can call it that. Yeah.
S3 (06:31):
Yeah. I mean, our work is always I mean, science is, uh,
we are doing collaborations and particularly our, our, um, we
are collaborating with people in, in Canada. We are collaborating
here with different people in Syria. And again, the idea is,
is to improve, um, the treatments we are having now
for glaucoma that we know they are not perfect. And
(06:53):
that's the idea. We are working all together for that. Yeah.
One of the.
S2 (06:56):
Things that, uh, I've talked to people about on this program, uh, Louise, like, um, often, um,
or not often, but occasionally you might get someone, you
know who might have been diagnosed with glaucoma in their
very young years. I mean, generally, we kind of associate with, uh,
an older person's disease. Is there more than one type
of glaucoma?
S3 (07:14):
Absolutely, absolutely. This is actually this is the the main
thing in our work because there is people that present
obviously clear high intraocular pressure, but there is a lot
of people that they don't present high pressure into the eye.
So we are wondering, for example, these are two big
(07:35):
subsets of of glaucoma. Yeah, but there are many more.
There are many more, as you say. There are many more.
But look at that. I mean, there is two big
groups of people with glaucoma. One of them present these
high intraocular pressure. Our treatments currently is decreasing intraocular pressure.
But there is another very big group of people with
(07:56):
glaucoma that they don't have high intraocular pressure. So this
is why our unit is trying to find what is
behind glaucoma. Besides the high intraocular pressure. So to to
answer to your question, yes, there are many groups of
suffering from glaucoma and not all of them are sharing
(08:16):
the same features. That's correct.
S2 (08:18):
And obviously, uh, from that, not every, uh, treatment or
not every particular Q is going to be the same either.
S3 (08:24):
Yes, exactly. That's exactly. So we are trying to add
different treatments to to this disease to, you know, personalize
at the end the glaucoma of each person. Yeah.
S2 (08:34):
The intraocular pressure. Is that kind of related to other
parts of the body? I'm thinking, you know, the sort
of conventional blood pressure, if you like. I mean, if
someone is, uh, diagnosed with hypertension, does that mean there
might be more prone to glaucoma?
S3 (08:46):
That is, there is there is this kind of study
showing these kind of things, but intraocular pressure is a
little bit different. What we are having intraocular pressure is
the pressure. Let's say, um, how can I explain. So
it's like an a ball, the pressure that is the
force that is pushing the walls of the um, internally,
the walls of the of the balloon of the words
(09:08):
or the, the, the walls of, of the ball. So
this is what we are having. So how we are
producing that, for example, we have liquids into the eye.
So this the, the eye is starting to produce more
liquids let's say. And then you can increase the pressure
because you have more liquid. So then the force against
the wall is higher. Now related to the the blood pressure. Yeah, definitely.
(09:30):
It's um, we know that people with high intraocular pressure is, um,
they present more often glaucoma. We there is this kind
of studies. Absolutely.
S2 (09:39):
Okay. But I guess then you might get someone who
hasn't got high blood pressure, has got glaucoma or vice versa. So,
you know, you might come up with this there, and
then all of a sudden you got these, the exceptions
to the rule that probably, you know, make you scratch
your head just a little bit more. Yeah.
S3 (09:54):
Absolutely, absolutely.
S2 (09:55):
So, um, I mean, I guess, you know, with, um,
you know, Glaucoma Week and World Glaucoma Day, the kind
of overriding message still is that, um, if it's in
your family. You got to get tested, you know, from
a younger age, if it's not in your family, you've
still got to get tested as you get older.
S3 (10:10):
Absolutely, absolutely. We always know. I mean, nowadays, I mean,
currently the main thing is prevention is to see that
you are potentially patient, let's say, or a person who
can suffer from glaucoma. As soon as we can know that,
it's going to be more easy to to treat the disease.
So yeah, that's that's a good message. What about.
S2 (10:31):
That? The genetic component, uh, you talked about, uh, you know, the, the, uh,
vascular work that you're doing, the genetic work. I know, uh,
speaking to people from Sarah over the years, there's a
lot of work going on in the genetic area as well.
S3 (10:45):
Yeah, yeah, yeah, this is very important, actually. One very
important member of our team. Um, one collaborator, Professor Keith Martin,
is working in this part, and he's giving us all
the expertise related to that. Um, but this is very important. Now,
we are seeing that these extremely important, uh, different approaches
that we again, he's trying to establish new treatments based
(11:09):
on genetic studies. So yeah. No, it's definitely very, very
important now it's fascinating isn't it?
S2 (11:14):
I guess like a lot of these things, sometimes one
breakthrough in one area might lead to other breakthroughs in
other areas for other conditions. Maybe not just eye conditions
as well.
S3 (11:24):
Absolutely, absolutely. Anything that we can find here, for example,
can be applied to other, uh, neurodegenerative diseases. This is
a good thing of, of this studies. And, and this
is one of the keys why we are getting funded.
Because it's not just for for glaucoma is is for
any neurodegenerative disease that we are seeing Alzheimer for example,
(11:47):
Parkinson is very related to these vascular alterations. So anything
we can get here can be applied to to other
big diseases too.
S2 (11:55):
And of course there are all kinds of disease of
the aging or a lot of them are related to age,
if you like. And we are an aging population. So,
you know, there might be younger people listening in saying, well,
you know, I'm 20, I'm 30 on 40. I don't
have to worry about that. But if they want to
live to 80, 90 or 100, then, you know, they've
got to start thinking about it at some stage.
S3 (12:14):
Absolutely. It's going to get to them. I mean, at
the end, you know, this is important. This is a
good point. Um, yeah. Again, as soon as we can
treat I mean, potential, uh, glaucoma people suffering from glaucoma,
I mean, it would be great. So if you can.
I mean, the sooner the better, for sure. Yeah.
S2 (12:31):
And I noticed from your website that, uh, you know,
you're often, um, sort of, uh, asking for people to
kind of, you know, uh, be part of your research.
Is that something that people are kind of accepting or, uh,
sort of signing up for a little bit more, do
you think, to, to become.
S3 (12:46):
Part of the, of our research, to be.
S2 (12:48):
Just or just research in general, I guess, get yours
in particular, but just in general, but.
S3 (12:53):
Participants you mean like people? Yeah. Yeah. Uh, we are
now working with now with, with people because our, our
research is more basic research. We are trying to understand
the basic. So we are using models, but definitely I
mean I think I'm feeling that that people is getting
because you are seeing in the different meetings we are doing,
for example, this glaucoma week, etc., you are seeing that
(13:15):
that is open for everyone and more and more people
is coming. So yeah, I feel that the people is
happy to to to join for sure.
S2 (13:24):
That's Doctor Luis Alarcon Martinez from the center for AI research.
We'll put a link up to some of the work
that they're doing on our Facebook page. But, uh, my word,
they're just speaking to, uh, these guys, uh, every now
and then, it's a wonderful insight into the tremendous work
that's going on. And I think Australia can be very,
very proud of that. Our researchers.
S4 (13:45):
Thank you for listening to Vision Xtra with Peter Greco.
You can find this interview on the Focal Point Podcast.
This show was produced in the Adelaide studios of Vision
Australia Radio.
On Vision Australia Radio this is Vision Xtra with Peter Greco.
S2 (00:22):
Well. Glaucoma week. Glaucoma world glaucoma day. They're very important topics.
Let's chat about it with Doctor Luis Alarcon Martinez from
the center for Eye Research, who is great to catch
up with you. Thanks so much for your time.
S3 (00:35):
It's a pleasure for me being here. Peter, thank you
so much.
S2 (00:37):
We've spoken about glaucoma for many, many years on this program.
You're very much involved with the research. What sort of
areas in the new ways that are being looked at
as far as glaucoma research go?
S3 (00:48):
Well, I mean, we are doing here in in Syria,
we have been doing a lot of things. A lot
of groups are working in trying to, you know, to
solve this disease, to give a better treatment for this disease. And,
and yeah, there are many, many new units. I mean,
we can talk about a couple of them, but particularly
particular what we are doing here in our unit, as
you know, is the neurovascular unit. We are trying to
(01:11):
give a different perspective for the new treatments for glaucoma.
S2 (01:15):
Yeah. Tell us a bit about that because you work
in that neurovascular area. Why is that kind of important.
S3 (01:22):
Yeah, that's a great question Peter. Well, as you know,
glaucoma is is is a neurodegenerative disease, is a disease
that affects the vision of people suffering from this disease.
And we always say that is related to high intraocular pressure,
the pressure that is, you know, into the eye that
is damaging the nerve cells that let us see. So unfortunately,
(01:46):
the treatments that we are having, they are not perfect.
So they can slow the disease, but we cannot cure
the disease. So in our unit, we are trying to
understand how these nerve cells, how these neurons that we
call they talk to the blood vessels, why these blood
vessels are important is because the neurons, the nerve cells
(02:06):
cannot keep energy. So they need to be asking all
the time for these energy to the blood vessels. So
we are thinking that this communication between neurons, nerve cells
and blood vessels is crucial. This is very important in
the in this disease. So we are studying that.
S2 (02:26):
So it's obviously very very what's the word sort of
um down a very micro level if you like. Yeah.
S3 (02:32):
Exactly what we are doing. That's a great point. What
we are doing in our unit is to look at
single nerve cells, one neuron talking to one vessel. So
for that we need a special, you know, equipment that
we are having here now in Sierra.
S2 (02:47):
That's the kind of say the, the the detail and
the communication line.
S3 (02:52):
If it is absolutely, absolutely is to see every single
detail in every single cell after, of course, we are
going to to to see what is happening globally in
the retina. But the first thing is going one by one.
S2 (03:03):
Yeah. And is that, um, you know, different to someone
that could have line of communication if you like. Is
that different to someone with glaucoma? That someone, uh, to
someone who has not got glaucoma?
S3 (03:13):
That's what we are seeing now. Exactly. What we are
seeing is that, uh, that's again, these are great question.
First thing we are trying to say is the, let's
say the the normal communication, let's say the communication in
people without glaucoma, let's say, and then after we are
moving to, to different models we have for glaucoma and
see how this communication is disrupted. But I can say
(03:36):
now here that we are seeing big differences in this
communication in, in, in models of glaucoma in different models
that we are having.
S2 (03:44):
And I guess the next question then is Luis okay, uh,
person I, if you like it is okay doesn't have glaucoma.
Person B does. The communication is different vastly different. What
makes it different. Why does that happen.
S3 (03:57):
Yeah. What we are seeing is that again these neurons
need energy. So we are seeing that these neurons, these
nerve cells again, these cells that let us seen because
it is they take the light and they transform this
light to electrical signal that goes to the brain. So
these neurons that in in people with glaucoma, they are
(04:17):
receiving less energy. So it means that, you know, a
long process in a long term they are going to
these neurons has to be, let's say more tired because yeah,
less energy in a period of a lifetime is going
to be a difference. Of course. Wow.
S2 (04:34):
That's amazing. And I guess, you know, in a sense
we can now understand why. Yeah, the message is, you know,
get yourself tested, uh, often and regularly if, if you
are a person with it in your family because the
earlier you, uh, diagnosis, the earlier you discovered, the more
time people have got for it to be treated and
sort of lessen the harm.
S3 (04:55):
Yes. That's correct. I mean, the idea is that if
this is really we can confirm all these findings, the
idea is to help to these neurons in people with
glaucoma to help. Them to have the energy that they
need all the time by increasing, for example, the blood supply.
By increasing this blood supply or maybe by other, other ways,
(05:15):
maybe keep this energy in a different way. But again,
this is this is the future. I mean, we are
still seeing this is correct. Yeah. Yeah.
S2 (05:23):
That's amazing isn't it? Can that kind of, um, you know,
relationship that communication line is what I'm calling it. Uh, uh,
can that be kind of, uh, replicated or taken to
other parts of the body in terms of, you know,
what happens and what might go wrong? Can you kind of, um,
expand the the research into other areas of the body?
S3 (05:43):
Do you mean, you know, the parts of the body,
like in the brain or something like that?
S2 (05:45):
Yeah, the brain or the heart sort of thing.
S3 (05:48):
Absolutely, absolutely. Uh. That's great. Um, exactly. I mean, what
we are seeing, where we hear we are talking about glaucoma,
but also we are, of course, studying the brain and diseases, uh,
stroke that is very important to all these bands of energy.
And you know, vascular supply etc. is extremely important. And
actually our unit has other, other studies going on in
(06:12):
different diseases related to the brain, for example. Yeah.
S2 (06:14):
The work that you're doing, is it being replicated in
other parts of the world. You kind of, uh, interact
with other, uh, you know, uh, research labs, etc. to
kind of, uh, collaborate and, and, uh, sort of, uh,
make the work, you know, work more, uh, you know,
more targeted, if I can call it that. Yeah.
S3 (06:31):
Yeah. I mean, our work is always I mean, science is, uh,
we are doing collaborations and particularly our, our, um, we
are collaborating with people in, in Canada. We are collaborating
here with different people in Syria. And again, the idea is,
is to improve, um, the treatments we are having now
for glaucoma that we know they are not perfect. And
(06:53):
that's the idea. We are working all together for that. Yeah.
One of the.
S2 (06:56):
Things that, uh, I've talked to people about on this program, uh, Louise, like, um, often, um,
or not often, but occasionally you might get someone, you
know who might have been diagnosed with glaucoma in their
very young years. I mean, generally, we kind of associate with, uh,
an older person's disease. Is there more than one type
of glaucoma?
S3 (07:14):
Absolutely, absolutely. This is actually this is the the main
thing in our work because there is people that present
obviously clear high intraocular pressure, but there is a lot
of people that they don't present high pressure into the eye.
So we are wondering, for example, these are two big
(07:35):
subsets of of glaucoma. Yeah, but there are many more.
There are many more, as you say. There are many more.
But look at that. I mean, there is two big
groups of people with glaucoma. One of them present these
high intraocular pressure. Our treatments currently is decreasing intraocular pressure.
But there is another very big group of people with
(07:56):
glaucoma that they don't have high intraocular pressure. So this
is why our unit is trying to find what is
behind glaucoma. Besides the high intraocular pressure. So to to
answer to your question, yes, there are many groups of
suffering from glaucoma and not all of them are sharing
(08:16):
the same features. That's correct.
S2 (08:18):
And obviously, uh, from that, not every, uh, treatment or
not every particular Q is going to be the same either.
S3 (08:24):
Yes, exactly. That's exactly. So we are trying to add
different treatments to to this disease to, you know, personalize
at the end the glaucoma of each person. Yeah.
S2 (08:34):
The intraocular pressure. Is that kind of related to other
parts of the body? I'm thinking, you know, the sort
of conventional blood pressure, if you like. I mean, if
someone is, uh, diagnosed with hypertension, does that mean there
might be more prone to glaucoma?
S3 (08:46):
That is, there is there is this kind of study
showing these kind of things, but intraocular pressure is a
little bit different. What we are having intraocular pressure is
the pressure. Let's say, um, how can I explain. So
it's like an a ball, the pressure that is the
force that is pushing the walls of the um, internally,
the walls of the of the balloon of the words
(09:08):
or the, the, the walls of, of the ball. So
this is what we are having. So how we are
producing that, for example, we have liquids into the eye.
So this the, the eye is starting to produce more
liquids let's say. And then you can increase the pressure
because you have more liquid. So then the force against
the wall is higher. Now related to the the blood pressure. Yeah, definitely.
(09:30):
It's um, we know that people with high intraocular pressure is, um,
they present more often glaucoma. We there is this kind
of studies. Absolutely.
S2 (09:39):
Okay. But I guess then you might get someone who
hasn't got high blood pressure, has got glaucoma or vice versa. So,
you know, you might come up with this there, and
then all of a sudden you got these, the exceptions
to the rule that probably, you know, make you scratch
your head just a little bit more. Yeah.
S3 (09:54):
Absolutely, absolutely.
S2 (09:55):
So, um, I mean, I guess, you know, with, um,
you know, Glaucoma Week and World Glaucoma Day, the kind
of overriding message still is that, um, if it's in
your family. You got to get tested, you know, from
a younger age, if it's not in your family, you've
still got to get tested as you get older.
S3 (10:10):
Absolutely, absolutely. We always know. I mean, nowadays, I mean,
currently the main thing is prevention is to see that
you are potentially patient, let's say, or a person who
can suffer from glaucoma. As soon as we can know that,
it's going to be more easy to to treat the disease.
So yeah, that's that's a good message. What about.
S2 (10:31):
That? The genetic component, uh, you talked about, uh, you know, the, the, uh,
vascular work that you're doing, the genetic work. I know, uh,
speaking to people from Sarah over the years, there's a
lot of work going on in the genetic area as well.
S3 (10:45):
Yeah, yeah, yeah, this is very important, actually. One very
important member of our team. Um, one collaborator, Professor Keith Martin,
is working in this part, and he's giving us all
the expertise related to that. Um, but this is very important. Now,
we are seeing that these extremely important, uh, different approaches
that we again, he's trying to establish new treatments based
(11:09):
on genetic studies. So yeah. No, it's definitely very, very
important now it's fascinating isn't it?
S2 (11:14):
I guess like a lot of these things, sometimes one
breakthrough in one area might lead to other breakthroughs in
other areas for other conditions. Maybe not just eye conditions
as well.
S3 (11:24):
Absolutely, absolutely. Anything that we can find here, for example,
can be applied to other, uh, neurodegenerative diseases. This is
a good thing of, of this studies. And, and this
is one of the keys why we are getting funded.
Because it's not just for for glaucoma is is for
any neurodegenerative disease that we are seeing Alzheimer for example,
(11:47):
Parkinson is very related to these vascular alterations. So anything
we can get here can be applied to to other
big diseases too.
S2 (11:55):
And of course there are all kinds of disease of
the aging or a lot of them are related to age,
if you like. And we are an aging population. So,
you know, there might be younger people listening in saying, well,
you know, I'm 20, I'm 30 on 40. I don't
have to worry about that. But if they want to
live to 80, 90 or 100, then, you know, they've
got to start thinking about it at some stage.
S3 (12:14):
Absolutely. It's going to get to them. I mean, at
the end, you know, this is important. This is a
good point. Um, yeah. Again, as soon as we can
treat I mean, potential, uh, glaucoma people suffering from glaucoma,
I mean, it would be great. So if you can.
I mean, the sooner the better, for sure. Yeah.
S2 (12:31):
And I noticed from your website that, uh, you know,
you're often, um, sort of, uh, asking for people to
kind of, you know, uh, be part of your research.
Is that something that people are kind of accepting or, uh,
sort of signing up for a little bit more, do
you think, to, to become.
S3 (12:46):
Part of the, of our research, to be.
S2 (12:48):
Just or just research in general, I guess, get yours
in particular, but just in general, but.
S3 (12:53):
Participants you mean like people? Yeah. Yeah. Uh, we are
now working with now with, with people because our, our
research is more basic research. We are trying to understand
the basic. So we are using models, but definitely I
mean I think I'm feeling that that people is getting
because you are seeing in the different meetings we are doing,
for example, this glaucoma week, etc., you are seeing that
(13:15):
that is open for everyone and more and more people
is coming. So yeah, I feel that the people is
happy to to to join for sure.
S2 (13:24):
That's Doctor Luis Alarcon Martinez from the center for AI research.
We'll put a link up to some of the work
that they're doing on our Facebook page. But, uh, my word,
they're just speaking to, uh, these guys, uh, every now
and then, it's a wonderful insight into the tremendous work
that's going on. And I think Australia can be very,
very proud of that. Our researchers.
S4 (13:45):
Thank you for listening to Vision Xtra with Peter Greco.
You can find this interview on the Focal Point Podcast.
This show was produced in the Adelaide studios of Vision
Australia Radio.
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Special Summer Offer: Exclusively on Apple Podcasts, try our Dateline Premium subscription completely free for one month! With Dateline Premium, you get every episode ad-free plus exclusive bonus content.
On Purpose with Jay Shetty
I’m Jay Shetty host of On Purpose the worlds #1 Mental Health podcast and I’m so grateful you found us. I started this podcast 5 years ago to invite you into conversations and workshops that are designed to help make you happier, healthier and more healed. I believe that when you (yes you) feel seen, heard and understood you’re able to deal with relationship struggles, work challenges and life’s ups and downs with more ease and grace. I interview experts, celebrities, thought leaders and athletes so that we can grow our mindset, build better habits and uncover a side of them we’ve never seen before. New episodes every Monday and Friday. Your support means the world to me and I don’t take it for granted — click the follow button and leave a review to help us spread the love with On Purpose. I can’t wait for you to listen to your first or 500th episode!